Biography & Research:
Ying Peng, Ph.D., is professor of Pharmacology in the institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC). She obtained her Ph. D. degree in Peking Union Medical College in 2004 and received a postdoctoral fellowship in Center for Neurologic Disease at Brigham & Women’s Hospital, Harvard Medical School. Dr. Peng’s research is focused on the molecular pathogenesis and drug development of Alzheimer’s disease (AD). Dl-3-n-butylphthalide (NBP) is a new drug which was approved by the State Food and Drug Administration (SFDA) of China for clinical use in stroke patients in 2002. NBP is a chiral compound, and contains L- and D- isomers. Dr. Peng firstly found that L-NBP significantly alleviated the learning and memory deficits in multiple AD animal models. Further, she explored the mechanisms of L-NBP, including inhibiting Aβ deposition, regulating APP processing, reducing neuroinflammation and oxidative stress, and promoting neurogenesis and neuroplasticity. She is currently working to develop the new neuroprotectant to delay or treat AD.